Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22848351 | 0.89 | KRAS (0.48) | KRASSOS1 | |
| SCHEMBL24436722 | 0.84 | KRAS (0.43) | KRASSOS1 | |
| SCHEMBL24436619 | 0.81 | KRAS (0.40) | KRASSOS1 | |
| SCHEMBL24436038 | 0.81 | KRAS (0.38) | KRAS | |
| SCHEMBL24436202 | 0.81 | KRAS (0.49) | KRASSOS1 | |
| SCHEMBL23272886 | 0.78 | KRAS (0.61) | KRASSOS1 | |
| SCHEMBL25887880 | 0.77 | KRAS (0.61) | KRAS | |
| SCHEMBL23324760 | 0.77 | KRAS (0.61) | KRASSOS1 | |
| SCHEMBL24436395 | 0.74 | KRAS (0.38) | KRASSOS1 | |
| SCHEMBL22848275 | 0.74 | KRAS (0.42) | KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153741-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12C | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2022-05-19 | — | — | US | disclosed |
| WO-2020259513-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12C | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2020-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153741-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KRAS 1/4885SOS1 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.